Continuation Versus Interruption of Renin-Angiotensin System Inhibitors in Acute Decompensated Heart Failure: A Brief Report

J Cardiovasc Pharmacol Ther. 2022 Jan-Dec:27:10742484221100127. doi: 10.1177/10742484221100127.

Authors

Christian A Bernhardi¹, Stephen Fendt², Brent N Reed³, Gautam Ramani⁴, Stormi E Gale⁵

Affiliations

¹ 536507Luminis Health Anne Arundel Medical Center, Annapolis, MD, USA.
² 15513University of Maryland School of Pharmacy, Baltimore, MD, USA.
³ Department of Pharmacy Practice and Science, 15513University of Maryland School of Pharmacy, Baltimore, MD, USA.
⁴ 12264University of Maryland School of Medicine, Baltimore, MD, USA.
⁵ 24963Novant Health Matthews Medical Center, Matthews, NC, USA.

PMID: 35543270
DOI: 10.1177/10742484221100127

Abstract

This article is temporarily under embargo.

Keywords: heart failure; renin-angiotensin aldosterone system.

MeSH terms

Angiotensin Receptor Antagonists / adverse effects
Angiotensin-Converting Enzyme Inhibitors / adverse effects
Antihypertensive Agents / therapeutic use
Heart Failure* / diagnosis
Heart Failure* / drug therapy
Humans
Hypotension* / chemically induced
Hypotension* / diagnosis
Renin-Angiotensin System
Retrospective Studies
Stroke Volume
Ventricular Function, Left

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents